Determining Risk Factors of Bleeding in Patients on Warfarin Treatment

Table 2

Dose and duration of warfarin use and laboratory results of 128 patients using warfarin with bleeding-related (SG) and non-bleeding-related (CG) reasons for their emergency department visits.

	CG			SG
	Min–max	Mean ± SD	Median [25–75% quartiles]	Min–max	Mean ± SD	Median [25–75% quartiles]
Age; (years)	23–88	61.9 ± 14.5	—	23–91	62.0 ± 14.4	—	0.970
Dose; (mg/week)	17.5–42.5	25.36 ± 8.24	22.5 [17.5–35.0]	8.75–70.0	30.17 ± 13.42	35 [17.5–35.0]	0.053
Duration; (months)	1–276	49 ± 59	24 [10–72]	1–288	53 ± 60	24 [12–72]	0.583
INR	0.88–11.00	2.63 ± 1.71	2.19 [1.64–3.03]	1.08–18.30	5.45 ± 3.98	4.46 [2.38–6.70]	<0.001
Hemoglobin; (g/dL)	7.4–16.4	12.46 ± 2.12	12.60 [10.90–14.2]	4.9–17.1	11.10 ± 2.68	11.1 [9.05–13.40]	0.005
Platelet count; (10^3/μL)	109–489	246 ± 80	229 [188–306]	81–585	266 ± 96	247 [204–309]	0.231
AST (U/L)	10.3–71.6	29.3 ± 14.6	23.9 [19.1–36.4]	9.2–149.0	33.0 ± 24.2	25.3 [19.9–35.4]	0.710
ALT (U/L)	5.3–94.0	22.4 ± 14.5	17.8 [13.7–25.3]	3.7–136.0	23.4 ± 21.2	17.5 [14.0–23.4]	0.598
Creatinine; (mg/dL)	0.5–2.7	0.9 ± 0.4	0.8 [0.7–1.1]	0.5–3.1	1.1 ± 0.6	1.0 [0.7–1.4]	0.042
BUN; (mg/dL)	13.2–132.1	37.6 ± 21.8	32.3 [26.4–40.1]	12.9–199.2	50.3 ± 33.8	39.1 [28.7–58.3]	0.009
CRP; (mg/dL)	0.09–271.97	15.46 ± 38.38	4 [1.5–12.8]	0.07–369.90	39.83 ± 66.31	13.50 [2.70–57.20]	0.002